Gasbjerg, Lærke S.

Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals.

Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 193

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study

Bergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., et al. (2019) · Diabetologia

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 142

The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor

Asmar, M., Asmar, A., Simonsen, L., Gasbjerg, L. S., Sparre-Ulrich, A. H., Rosenkilde, M. M., Hartmann, B., Dela, F., Holst, J. J., & Bülow, J. (2017) · Diabetes

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 132

Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists

Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 121

Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents

Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 85

LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men

Hagemann, C. A., Jensen, M. S., Holm, S., Gasbjerg, L. S., Byberg, S., Skov-Jeppesen, K., Hartmann, B., Holst, J. J., Dela, F., Vilsbøll, T., et al. (2022) · Cell Reports Medicine

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 81

GIP and GLP-1 receptor antagonism during a meal in healthy individuals

Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., Christensen, M. B., Vilsbøll, T., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 68

Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease

Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides

Adipokines, Inflammation, and Metabolic DiseasesDiabetes Treatment and Management

Cited by 67

No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes

Bergmann, N. C., Gasbjerg, L. S., Heimbürger, S. M., Krogh, L. S. L., Dela, F., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 62

The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes

Dalsgaard, N. B., Gasbjerg, L. S., Hansen, L. S., Hansen, N. L., Stensen, S., Hartmann, B., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2021) · European Journal of Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 37

GIP’s involvement in the pathophysiology of type 2 diabetes

Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020) · Peptides

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 35